Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Framycetin

    go.drugbank.com/drugs/DB00452
    ApprovedInvestigational

    A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)

    International brands: Leukase N
  2. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.

  3. Drug

    Trichophyton rubrum

    go.drugbank.com/drugs/DB10915
    Approved

    Trichophyton rubrum is a fungus which can provoke allergic reactions. Trichophyton rubrum extract is used in allergenic testing.

    Mixtures: Trichophyton for Intradermal Skin Testing
  4. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

  5. Drug

    Radium Ra 223 dichloride

    go.drugbank.com/drugs/DB08913
    ApprovedInvestigational

    The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. … As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases.

    Synonyms: Radium chloride Ra-223, Radium (Ra-223) dichlorideProducts: Radium Ra 223 Dichloride, XOFIGO SOLUTION FOR INJECTION 1100kBq/ML
  6. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.

  7. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada. … Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug.

    Categories: Drugs for Functional Gastrointestinal Disorders
  8. Drug

    Interferon alfacon-1

    go.drugbank.com/drugs/DB00069
    ApprovedWithdrawn

    Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … This protein has a molecular weight of 19,434 daltons.

  9. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. … While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis

  10. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

    Categories: Corticosteroids for Systemic Use